ImpediMed Limited Overview
ImpediMed is a small-cap Australian medical-technology company that commercialises bioimpedance spectroscopy (BIS) through its SOZO® Digital Health Platform — a hand-and-foot-plate measurement device paired with cloud software (MySOZO) that delivers non-invasive fluid and tissue-composition metrics in roughly 30 seconds. Its anchor indication is the early detection of breast-cancer-related lymphoedema (BCRL) via the proprietary L-Dex® score, for which ImpediMed describes itself as the only company offering FDA-cleared BIS technology. Commercial traction rests on three pillars built over 2023–2026: inclusion of BIS in NCCN Survivorship Guidelines and NAPBC breast-centre standards, a dedicated CPT code (93702), and US payer coverage that reached 95.0% of covered lives (331M) by June 2026. Around 90% of revenue is US-derived. The company is now extending SOZO into heart failure (HF-Dex) and GLP-1-era body composition, but remains loss-making (FY2026 net loss A$24.9M on A$14.6M revenue), heavily diluted, and dependent on further capital.
What the company does
ImpediMed designs, manufactures (via outsourced/contract arrangements; manufacturer of record on FDA filings is ImpediMed Limited, Australia) and sells medical devices that apply bioimpedance spectroscopy — passing a low-level electrical current through the body across a spectrum of frequencies — to estimate extracellular fluid, intracellular fluid, total body water, and body-composition parameters (fat mass, fat-free mass, skeletal muscle mass). The flagship SOZO system (and successor SOZO Pro) is used under physician direction for:
Lymphoedema assessment: (L-Dex®), primarily in breast-cancer survivorship programmes — the "SOZO Core Business";
Heart failure fluid monitoring: (HF-Dex), including patients with cardiac implantable devices (SOZO Pro clearance, Oct 2023);
- Protein-calorie malnutrition / body composition, including the newly targeted GLP-1 weight-management and sarcopenia use-cases.
Company's own description (paraphrased from FY2026 H1 and FY2026 Q4 releases)
ImpediMed describes itself as a medical technology company using BIS to generate data that maximise patient health, producing the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked and ARTG-listed for multiple indications (lymphoedema, heart failure, protein-calorie malnutrition), and sold in select markets globally. It positions SOZO as part of the patient journey from active cancer treatment through long-term survivorship monitoring, and frames the large cancer-related lymphoedema market as an opportunity for growth through its SaaS subscription-based business (Appendix 4D H1 FY26, 26 Feb 2026; Q4 FY26 Appendix 4C, 28 Jul 2026).
Business and revenue model
Contract structure: Customers (predominantly US hospitals, cancer centres and integrated delivery networks) sign multi-year agreements — typically three years — that include consideration for the SOZO unit plus licence/usage fees for the contract duration (definition of Total Contracted Value, Appendix 4D H1 FY26).
Revenue recognition: Since Q2 FY24 the company reports all revenue associated with each contract as revenue from contracts with customers rather than separating "device" and "recurring subscription" revenue (Q2 FY24 Quarterly Report). Recurring usage fees are dominant: in H1 FY26, SOZO recurring usage fees were A$7.2M of A$7.5M total revenue (≈96%), up 26% YoY (Appendix 4D H1 FY26).
Key KPIs: Annual Recurring Revenue (ARR — next-12-month revenue expected from existing contracts, assuming installation and no churn), Total Contract Value (TCV — new and renewed contracts), units sold, covered lives, churn and renewal pricing.
Revenue mix (by type): Predominantly SaaS/recurring licence (≈96% in H1 FY26); small device/distributor sales (e.g., the Australian distributor's 38-unit order in Q2 FY26); legacy devices and consumables (L-Dex U400 / SFB7-era products) now immaterial; clinical-trial revenue (AstraZeneca programme) ceased in FY24.
Gross margin: High software-like gross margins — 86% (FY2023), 87% (FY2024), 86% (FY2025), 87% (FY2026) (FY24 results release; FY26 results summary).
Value-chain position
ImpediMed sits at the device-plus-software layer of the point-of-care diagnostics value chain: it owns IP, algorithms (L-Dex, HF-Dex scoring), regulatory clearances and the cloud platform, while outsourcing much of the hardware supply chain (the company referenced long-lead electronic component payments in Q1/Q2 FY26 Appendix 4C commentary). It sells direct in the US through a field sales force and via distributors elsewhere (e.g., Australia).
Customer types and end markets
| Customer type | Evidence (source) |
|---|---|
| US cancer centres / breast centres | 172 of the top 500 US cancer centres are customers, including 24 of 33 NCCN centres (H1 FY26 investor materials as reported by StockWire X, Feb 2026) |
| Integrated delivery networks (IDNs) | 17 of the 20 top IDNs by patient revenue are customers (same source); SOZO deployed across all 15 of the top 15 US IDNs offering lifestyle medicine/primary care programmes (Appendix 4D H1 FY26) |
| Top US hospitals | SOZO in 18 of the top 25 US hospitals; ~600 devices deployed in the US at H1 FY26 and 642 installed at Q4 FY26 |
| Heart failure programmes | First Heart Health sale to an IDN in Texas (H1 FY26) |
| Weight-loss, lifestyle-medicine and wellness clinics | Body-composition launch, 3.5 dedicated sales reps, 3,000+ leads (H1 FY26) |
| International distributors | Australian distributor ordered 38 units in Q2 FY26 (Q2 FY26 Appendix 4C) |
| Pharma clinical trials (historic) | AstraZeneca clinical-trial programme; revenue fell from A$2.0M (FY23) to A$0.1M (FY24) (FY24 results release) |
Independent characterisation
ImpediMed is effectively a single-product, single-geography (US) oncology-survivorship SaaS business with ~A$14–15M of recurring-heavy revenue, an installed base of ~640 US units, and a structurally unprofitable cost base (FY2026 operating cash burn A$17.9M). Its moat is regulatory and guideline-based rather than technological scale: it holds the only FDA-cleared BIS lymphoedema indication, has guideline endorsement (NCCN, NAPBC), a dedicated CPT code, and near-universal US payer coverage. However, conversion of that clinical/reimbursement position into unit growth has repeatedly lagged expectations (Canaccord, Feb 2026, noted the anticipated sales acceleration had yet to arrive). The diversification into heart failure and GLP-1 body composition is strategically logical (same hardware, existing hospital contracts and IT/security approvals) but is at a very early stage, while the balance sheet is fragile (going-concern doubt in FY2026 accounts, per Capital IQ headline).
Strategy
Stated strategy (themes from FY2026 reporting)
Deepen the lymphoedema/cancer-survivorship franchise: drive utilisation and growth in existing accounts; leverage NCCN/NAPBC inclusion and 95% reimbursement coverage; renewal price escalators (+14% avg Q2 FY26; +6.7% Q4 FY26).
"Three markets, one platform": extend SOZO into Heart Health (HF-Dex/SOZO Pro) and Weight Management/body composition (GLP-1 era), which management describes as capital-light because they reuse hardware, contracts and health-system approvals.
Progress toward cash-flow breakeven: A$5.0M annualised operating cost reduction (implemented Q4 FY26, realised evenly over FY27); operating cash-flow breakeven targeted in FY28 (H2 FY28 per investor presentation), assuming full exercise of options.
Commercial execution under a US medtech operator CEO: focus on health-system procurement and adoption; new sales and retention leadership roles.
Strategic partnerships: management signalled openness to partnerships (Q4 FY26 call summary).
FY27 priorities (FY26 results): deepen lymphoedema and survivorship platform; drive utilisation and growth in current accounts; scale Heart Health and Weight Management; progress toward cash-flow breakeven.
Initiatives register (last 24 months)
| Date | Initiative | Detail / targets |
|---|---|---|
| Q4 FY24 → FY25 | Cost reduction | FY25 cash expenditure targeted −10%; achieved −16% vs FY24 |
| Feb 2025 | Debt growth capital | SWK US$15M facility |
| FY25 | SOZO Pro next-gen platform | Introduced for advanced fluid and body-composition use |
| FY25 | Heart-failure evidence | 116-patient investigator-initiated observational HF trial |
| H1 FY26 | Heart Health commercial launch | First IDN sale (Texas); 2 dedicated reps; THT Boston (2–4 Mar 2026) |
| H1 FY26 | Weight-management launch | 3.5 reps; 3,000+ leads; A$650M addressable market claim |
| H1 FY26 | Sarcopenia 510(k) | Filed with FDA; outcome pending |
| May 2026 | Capital raise + cost-out | A$15.2–15.3M equity; A$5.0M annualised savings; SWK amendment and A$5.0M prepayment |
| Jun 2026 | Commercial reorganisation | New leadership roles in sales and retention |
| Q4 FY26 | HF-Dex reimbursement mapping | State-by-state mapping to support field activity |
ESG/sustainability commitments: none specifically disclosed.
Medium-term targets / guidance
-
Operating cash-flow breakeven in FY28 (H2 FY28), contingent on full exercise of 1.32bn Attaching Options (A$0.010) and 1.32bn Follow-on Options (A$0.015), worth up to A$32.7M (4 May 2026 announcement; StockWire X).
-
No formal revenue guidance identified for FY27.
-
Earlier targets have slipped: an H2 FY24 summary referenced break-even targeted within two years, and the FY24 materials discussed moving toward cash-flow break-even — superseded by the FY28 target.
Products & Services
SOZO® (first-generation platform device)
| Attribute | Detail |
|---|---|
| Description | Standing/seated BIS device with hand and foot plates with stainless-steel electrodes; patient contacts electrodes with bare hands and feet |
| Key specifications | Standing weight capacity 170 kg (Stockhead, comparing to SOZO Pro) |
| Regulatory | FDA 510(k): K172122 (Aug 2017), K172507 (Dec 2017), K180126 (Apr 2018), K190529 (Nov 2019), K193410 (Oct 2020, "SOZO Body Fluid Analyzer"), K203473 (Apr 2021); CE-marked; ARTG-listed |
| Indications | Lymphoedema (L-Dex), heart failure (HF-Dex), protein-calorie malnutrition/body composition |
| Target customer | US cancer centres, hospitals, IDNs |
| Pricing model | Multi-year contract (typically 3 years) bundling unit consideration and licence/usage fees; renewal price increases averaged 14% in Q2 FY26 and 6.7% in Q4 FY26 |
SOZO® Pro (next-generation device)
| Attribute | Detail |
|---|---|
| Description | Next-generation BIS system with connected hand and footplate paired with an Android tablet via Bluetooth; load cells in the foot unit measure weight |
| Key specifications | Standing weight capacity 220 kg; updated stand design for easier transitions between standing and seated measurement (Stockhead, 2023) |
| Regulatory | Special 510(k)s K230530/K230531 (4 May 2023) for lymphoedema and protein-calorie malnutrition; traditional 510(k) K232089 (17 Oct 2023) for monitoring fluid in heart-failure patients, with demonstrated compatibility with pacemakers/ICDs per ISO 14117 test methods |
| Launch | Introduced in FY2025 (FY25 annual results); "SOZO Pro launched" referenced in Q2 FY26 materials; first Heart Health sale leveraged SOZO Pro (H1 FY26) |
| Target customer | Heart-failure programmes (patients with cardiac implantable devices), oncology, weight management |
MySOZO® software (cloud platform)
| Attribute | Detail |
|---|---|
| Description | Cloud-based software component of the SOZO Digital Health Platform; enables measurements with either SOZO or SOZO Pro and clinician review of fluid levels |
| Latest version | MySOZO Software 6.0.1.2 — FDA 510(k) K253224 (predicate K232089, reference K180126) |
| Pricing | Included in contract licence/usage fees (SaaS) |
| Integration | Health-system Business Associate Agreements and IT-security approvals already in place across many IDNs (H1 FY26) |
L-Dex® (lymphoedema index)
| Attribute | Detail |
|---|---|
| Description | Proprietary BIS-derived score for early detection of extremity lymphoedema, most commonly breast-cancer-related lymphoedema |
| Clinical/guideline support | NCCN Survivorship Guidelines (2023, reaffirmed 2024), NAPBC standards (Oct 2024); company states it is the only FDA-cleared BIS technology for clinical lymphoedema assessment |
| Reimbursement | CPT code 93702; US coverage 95.0% of covered lives (331M) at 30 Jun 2026, up from zero at start of FY24 |
| Evidence base | Company-sponsored PREVENT randomised trial (BIS-triggered vs tape-measure-triggered intervention) reported lower progression to chronic lymphoedema (2022 Annual Report narrative); details not re-verified |
HF-Dex™ (heart-failure fluid index)
| Attribute | Detail |
|---|---|
| Description | FDA-cleared index derived from extracellular fluid, presenting a patient's fluid levels over time against a normal range; ~30-second, non-invasive assessment |
| Claimed performance | HF-Dex identified patients with 4.25× higher 30-day readmission risk vs clinical judgement alone (H1 FY26 materials as reported by StockWire X) |
| Commercial status | First sale to a Texas IDN (H1 FY26); two dedicated Heart Health reps; state-by-state HF-Dex reimbursement mapping underway (Q4 FY26); 116-patient investigator-initiated observational HF trial (FY25 annual results) |
| Market sizing (company) | US$1.1bn heart-failure opportunity (Biotech Dispatch, citing company, FY25) |
Body composition / Weight management (incl. GLP-1 monitoring) and sarcopenia
| Attribute | Detail |
|---|---|
| Description | Body-composition metrics (fat mass, fat-free/skeletal muscle mass, fluid) to monitor lean-mass loss during weight-loss therapy; company states SOZO is the only BIS device FDA-cleared to assess body composition in an unhealthy patient population |
| Regulatory | Existing protein-calorie malnutrition/body-composition clearances; 510(k) filed for sarcopenia indication (H1 FY26) — decision not yet disclosed |
| Commercial status | Launch commenced H1 FY26; 3.5 dedicated reps; 3,000+ leads; targets weight-loss clinics, lifestyle-medicine practices and wellness clinics |
| Market sizing (company) | ~A$650M addressable market (H1 FY26); US$350M TAM in GLP-1-related body-composition scans (FY25 commentary) |
Legacy products
L-Dex U400 and earlier BIS devices plus consumables (electrodes) — referenced in Morningstar's description of revenue streams ("Legacy Devices and Consumables") and the Feb 2020 release; immaterial to current revenue.
Services
Clinical-trial measurement services (historic AstraZeneca programme), customer training/implementation, and reimbursement support (company runs reimbursement initiatives to help customers update guidelines and coverage, H1 FY26).
Financial Narrative
Data notes: FY2025 and FY2026 P&L items from Appendix 4E/annual results; FY2022–FY2024 from Appendix 4E FY2023 and FY24 results release; balance sheet FY2022–FY2025 from TipRanks aggregator (cross-checked against Kalkine net-debt series and company cash disclosures); EBITDA, EPS and several ratios not disclosed in sources reviewed.
Income statement
Sources: Appendix 4E FY2023 (FY22/FY23 revenue); FY24 results release (FY24 revenue, operating loss before tax FY23/FY24, GM FY23/FY24); FY25 annual report data via financialfilings.com (FY25 revenue A$12.72M, net loss A$23.24M); Appendix 4E FY2026 (revenue A$14.613M, loss after tax A$24.907M, no dividends); FY26 results summary (GM 87% vs 86%). FY2022/FY2023 net loss from Kalkine aggregator.
Other P&L disclosures:
-
EBITDA: not publicly disclosed in reviewed documents; the business is EBITDA-negative by roughly the scale of its operating loss (FNArena shows Debt/EBITDA of −0.74).
-
H1 FY26 detail: revenue A$7.5M (+25%), gross profit A$6.6M (87%), operating expenses net of other income A$17.4M (+3%), net finance expense A$1.4M (vs A$0.4M income in H1 FY25), loss before tax A$12.3M (+10%) (Appendix 4D H1 FY26).
-
FY2026 loss increase was attributed mainly to higher finance expenses (SWK facility) (FY26 results summary).
Revenue CAGR: FY2022→FY2026 (4 years): ~8.4% (derived). FY2021→FY2026 (5 years, FY21 revenue A$8.41M per TipRanks): ~11.7% (derived). Constant-currency FY2026 growth was 20% (A$15.3M CC) (FY26 results summary).
Commentary. Revenue has compounded at high-single to low-double digits, but the trajectory masks two distinct phases: FY2022–FY2024 was distorted by the run-off of AstraZeneca clinical revenue (−A$1.9M in FY24), while SOZO Core revenue grew 30%, 14% and 25% in FY23, FY24 and FY25 respectively. FY2026's 15% reported growth (20% CC) was driven by recurring usage fees (+26% in H1), renewal price escalators and installed-base growth, partially offset by a stronger AUD in H1 and a weaker AUD later (the ARR/TCV disclosures show currency noise in both directions). Gross margins are structurally excellent (86–88%), so the loss is entirely an operating-leverage problem: operating expenses of ~A$32.7M in FY2023 (FY24 release) against ~A$11M of revenue. Net losses have widened from ~A$20M to ~A$25M as finance costs rose post-SWK draw-down.
Key operating metrics
Sources/derivations: ARR FY23 A$9.3M and FY24 A$11.0M (2024 AGM deck; FY24 release, +18%); FY25 ARR ~A$14M (Biotech Dispatch, Q4 FY25); FY26 ARR A$14.4M (Q4 FY26 Appendix 4C). FY24 TCV A$9.4M (−29%), so FY23 ≈ A$13.2M (derived). FY26 TCV derived as H1 A$8.7M + Q3 A$5.4M + Q4 A$5.4M. Units FY24 113 (−16%), so FY23 ≈ 135 (derived). Tests FY24 250k (+18%), FY23 ≈ 212k (derived). Coverage FY25 87% (Biotech Dispatch, Q4 FY25); FY24 start zero covered lives (FY24 release).
FY2026 quarterly progression
Sources: Q2 FY26 Appendix 4C (29 Jan 2026); Q4 FY26 Appendix 4C (28 Jul 2026); Quartr/TickerSpark call summaries. Derived: Q3 ARR (Q4 A$14.4M was +2% QoQ); Q2 US units (57 global less 38 Australian distributor units); Q3 operating outflow (Q4 A$4.9M was A$0.5M higher); Q3 receipts (Q4 A$4.3M was A$1.0M higher). Discrepancy: Q1 FY26 operating outflow is reported as A$5.6M in a call summary but described as A$5.9M in the Q2 4C narrative; the A$5.6M figure reconciles better to the FY total of A$17.9M. H1 cash is shown as A$18.8M in the Appendix 4D vs A$18.9M in the Q2 4C (rounding/definition).
Balance sheet
Sources: TipRanks (FY22–FY25 balances); FY25 equity, assets and net loss cross-checked to financialfilings.com (FY25 annual report); Kalkine net-debt series (−44.26, −40.56, −23.49) matches derived net cash; FY26 cash A$15.3M (Appendix 4C Q4 FY26; FY26 results); NTA per security from Appendix 4E FY2026. Short/long-term debt split, goodwill & intangibles and working capital: not publicly disclosed in reviewed sources. Pro-forma net cash after the May 2026 raise was stated at A$5.9M (raise presentation summary, InvestSMART).
Debt detail. SWK Funding LLC 5-year US$15M growth capital facility (Feb 2025): Tranche 1 US$10M drawn on signing; Tranche 2 US$5M available subject to FY25 sales targets; liquidity covenant to maintain unrestricted cash of US$2.5M; all-in cash IRR to maturity of 15.8% including interest, establishment fee and back-end success fee; 12,491,870 warrants issued at an exercise price of A$0.05139 (ASX announcement 6 Feb 2025). The facility was amended in May 2026 and A$5.0M was prepaid from the equity raise (Q4 FY26 Appendix 4C). Remaining principal at 30 Jun 2026: not publicly disclosed in sources reviewed (implied roughly A$10M based on US$10M original draw less A$5M repayment, before FX — estimate only).
Cash flow: notes and sources
Sources: FY24 results release (FY24 A$17.8M; FY23 A$18.0M); FY25 annual report via financialfilings.com (A$14.64M); FY26 results summary (A$17.9M); Kalkine aggregator for FY22 operating cash flow and FY22/FY23 free cash flow and financing flows (aggregator year labels partly inconsistent; treat as indicative). Discrepancy: the FY26 results summary cites FY25 operating outflow of A$15.6M, versus A$14.64M in the FY25 annual report data — likely a definitional difference (e.g., inclusion/exclusion of interest or R&D incentive); both are noted. Capex: not separately disclosed; aggregator FCF implies ~A$5–6M p.a. of investing outflows in FY22–FY23, consistent with capitalised SOZO units/development.
Ratios (derived from year-end figures above)
ROIC, current ratio, net debt/EBITDA, interest coverage and cash conversion cycle: not meaningful (negative EBITDA/EBIT) or not publicly disclosed. Runway derived as year-end cash ÷ (annual operating outflow ÷ 4); management cited 6.3 quarters at end-FY25 (Biotech Dispatch) and 6.5 quarters at Q2 FY26 (Quartr), consistent with this method. FY2026 runway of ~3.4 quarters on trailing burn is before the A$5M cost-out and before any option exercise.
Trend commentary
-
Inflection in recurring revenue, not in profitability. ARR grew from A$9.3M (FY23) to A$14.4M (FY26), but ARR was flat at A$14.4M through every quarter of FY2026 in reported currency, signalling that new placements were only offsetting churn (FY26 churn rate 6.8% vs below 3% cited in FY25) and FX.
-
Cash burn is sticky. Operating outflows have ranged A$14.6–18.0M for five consecutive years despite two cost programmes (FY25 cash opex −16%; May 2026 A$5M annualised cut).
-
Balance-sheet deterioration. Equity fell from A$60.9M (FY23) to A$20.5M (FY25), and net tangible assets per share reached 0.00 cents at FY26. Debt became material only in FY25 (SWK), raising finance costs.
-
Dilution as the funding mechanism. The May–June 2026 raise issued ~1.62bn shares (≈+56% on the pre-raise ~2.34bn) and up to ~2.6bn+ options; full option exercise (A$32.7M) is embedded in management's FY28 breakeven pathway.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Revenue
| Category | What it contains |
|---|---|
SOZO Core Business | Revenue from SOZO contracts in the oncology/lymphoedema market (device consideration plus recurring licence/usage fees) |
Clinical | SOZO use in pharma clinical trials (AstraZeneca programme; ceased FY24) |
Legacy devices / other | Stand-alone legacy devices (e.g., L-Dex U400) and consumables; other income |
Emerging (from FY26) | Heart Health (HF-Dex) and Weight Management/body composition — not separately quantified; described as early commercial stage |
Revenue category (AUD Mn)
| Revenue category (AUD Mn) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
SOZO Core Business revenue | 6.6 | 8.5 | 9.7 | 12.1 | — |
Clinical revenue (AstraZeneca) | — | 2.0 | 0.1 | — | — |
Legacy devices and other (derived = total − core − clinical) | — | 0.8 | 0.5 | 0.6 | — |
Total revenue | 10.57 | 11.34 | 10.32 | 12.72 | 14.61 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
SOZO Core revenue growth YoY | — | 30 | 14 | 25 | — |
SOZO Core share of total revenue | 62 | 75 | 94 | 95 | — |
Total revenue growth YoY | 26 | 7 | -9 | 23 | 15 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue (AUD Mn) | 10.57 | 11.34 | 10.32 | 12.72 | 14.61 |
Revenue growth YoY (%) | 26 | 7 | -9 | 23 | 15 |
Gross margin (%) | — | 86 | 87 | 86 | 87 |
Gross profit (AUD Mn, derived = revenue × GM) | — | 9.75 | 8.98 | 10.94 | 12.71 |
Operating loss before tax (AUD Mn, company-defined) | — | -20.5 | -19.8 | — | — |
Net loss after tax (AUD Mn) | -19.87 | -20.52 | — | -23.24 | -24.91 |
Net margin (%, derived) | -188 | -181 | — | -183 | -170 |
Dividends per share (AUD) | 0 | 0 | 0 | 0 | 0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansKey Financials and Operating Metrics (units)
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
SOZO Core ARR at year end (AUD Mn) | 9.3 | 11.0 | 14.0 | 14.4 |
SOZO Core TCV signed (AUD Mn) | 13.2 | 9.4 | — | 19.5 |
Global SOZO units sold (units) | 135 | 113 | — | — |
US covered lives (millions) | 0 | 140 | 286 | 331 |
US national coverage (%) | 0 | — | 87 | 95 |
SOZO tests conducted (thousands) | 212 | 250 | — | — |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|
Revenue (AUD Mn) | 3.6 | 3.9 | 3.5 | 3.6 |
ARR (AUD Mn) | 14.4 | 14.4 | 14.1 | 14.4 |
SOZO Core TCV (AUD Mn) | 4.7 | 4.1 | 5.4 | 5.4 |
Global units sold | 45 | 57 | — | 40 |
US units sold | 26 | 19 | — | 36 |
US national BCRL coverage (%) | 87 | 92.8 | 94.3 | 95.0 |
Net operating cash outflow (AUD Mn) | 5.6 | 2.9 | 4.4 | 4.9 |
Cash receipts (AUD Mn) | — | 3.8 | 3.3 | 4.3 |
Cash at quarter end (AUD Mn) | — | 18.9 | — | 15.3 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash, equivalents and term deposits (AUD Mn) | 40.73 | 45.71 | 24.63 | 22.18 | 15.3 |
Total assets (AUD Mn) | 58.70 | 68.74 | 46.99 | 41.66 | — |
Total liabilities (AUD Mn) | 7.66 | 7.86 | 6.24 | 21.16 | — |
Total debt incl. leases (AUD Mn) | 0.17 | 1.45 | 1.14 | 14.49 | — |
Net cash (AUD Mn, cash − total debt) | 40.56 | 44.26 | 23.49 | 7.69 | — |
Total equity (AUD Mn) | 51.04 | 60.88 | 40.74 | 20.50 | — |
Net tangible assets per share (cents) | — | — | — | 0.37 | 0.00 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Net operating cash flow (AUD Mn) | -15.66 | -18.0 | -17.8 | -14.64 | -17.9 |
Free cash flow (AUD Mn, aggregator) | -20.89 | -24.09 | — | — | — |
Cash from financing (AUD Mn, aggregator) | 16.47 | 39.92 | — | — | — |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Gross equity raised (AUD Mn) | — | — | — | — | 15.3 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE (%, net loss / year-end equity) | -39 | -34 | — | -113 | — |
ROA (%, net loss / year-end assets) | -34 | -30 | — | -56 | — |
Debt to equity (x) | 0.00 | 0.02 | 0.03 | 0.71 | — |
Asset turnover (x, revenue / year-end assets) | 0.18 | 0.16 | 0.22 | 0.31 | — |
Cash runway (quarters, cash / avg quarterly op. outflow) | 10.4 | 10.2 | 5.5 | 6.1 | 3.4 |
Region revenue share (%)
| Region revenue share (%) | FY2024 |
|---|---|
United States (% of total revenue) | 90 |
Rest of world incl. Australia and Europe (% of total revenue) | 10 |
Geographic Revenue
| Units sold | Q1 FY26 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|
US units | 26 | 19 | 36 |
Rest of world units | 19 | 38 | 4 |
Global units | 45 | 57 | 40 |
Valuation Snapshot
| Metric | Value | Source / date |
|---|---|---|
Last observed price | ~A$0.005–0.0055 | InvestSMART 22 Sep 2026; MarketScreener 3 Sep 2026 |
YTD 2026 return | −83.8% | MarketScreener, 3 Sep 2026 |
6-month return | −67.7% | MarketScreener, 3 Sep 2026 |
3-month return | −21.4% | MarketScreener, 3 Sep 2026 |
1-year return (approx.) | ~−85% (≈A$0.036 at 18 Nov 2025 AGM → ≈A$0.005) | InvestSMART announcement price history (derived) |
3-year return (approx.) | Deeply negative; shares traded ~A$0.08–0.24 range in late 2023/early 2024 (Google Finance year range then) | — |
Placement price (May 2026) | A$0.010 (28.6% discount to A$0.014 close) | ASX 4 May 2026 |
SPP price (Jun 2026) | A$0.007 | ASX 10 Jun 2026 |
Balance Sheet
| Metric | FY2024 | FY2026 |
|---|---|---|
Shares on issue (millions, approx.) | 2,020 | 3,660 |
Gross equity raised (AUD Mn) | — | 15.3 |
Valuation Multiples
| Multiple | ImpediMed | Basis |
|---|---|---|
Market cap | ~A$18–20M | Price × 3.66bn shares |
EV/Sales (FY2026 actual) | ~1.0–1.5x | MarketScreener EV A$29.4M (may be stale) vs A$14.6M revenue; MarketScreener EV/Sales FY27E 1.5x, FY28E 1.0x |
P/E | Not meaningful (loss-making); MarketScreener P/E FY27E −1.65x, FY28E −3.64x | — |
EV/EBITDA | Not meaningful (negative EBITDA) | — |
P/B | Not meaningful (NTA per share 0.00c) | — |
Peer reference | Tactile Medical: US$329.5M revenue, profitable (US$19.1M net income, 2025) — trades on positive earnings multiples; direct multiple comparison not meaningful given scale/profit gap | — |
Analyst Ratings & Targets
| Broker | Rating | Target | Date |
|---|---|---|---|
Canaccord Genuity | Speculative Buy | A$0.06 (cut from A$0.07) | Feb 2026 |
Bell Potter | Speculative Buy | — | 30 Jan 2026 |
Morgans | Speculative Buy | — | 30 Jan 2026 |
FNArena consensus target | — | A$0.067 | Feb 2026 (pre-raise; likely stale) |
Ord Minnett | Speculative Buy | — | Apr 2024 |
Analyst Conclusions
Management guidance
-
FY27 priorities: deepen lymphoedema/survivorship platform; increase utilisation in existing accounts; scale Heart Health and Weight Management; progress toward breakeven (FY26 results).
-
A$5.0M annualised cost savings realised evenly over the next year (Q4 FY26 call).
-
Operating cash-flow breakeven in FY28 (H2 FY28), assuming full option exercise (May 2026).
-
No explicit revenue guidance.
Consensus expectations
MarketScreener-implied consensus (via EV/Sales of 1.5x FY27E and 1.0x FY28E on ~A$29M EV) suggests revenue of roughly A$20M in FY27 and ~A$29M in FY28 — implied figures only, derived from aggregator multiples, and potentially stale or based on very limited coverage.
Bull case
-
Reimbursement is solved; execution is the only gap. With 95% coverage, guideline status and ~700 pipeline units (vs ~642 installed), a commercially experienced CEO from Hologic's breast franchise could double the US installed base, and with 87% gross margins incremental revenue drops through powerfully.
-
Platform optionality is cheap. HF-Dex (US$1.1bn TAM claim) and GLP-1 body composition (A$650M claim) leverage existing contracts and IT approvals; even modest traction is large relative to an ~A$20M market cap.
-
Strategic value. Unique FDA clearances (BIS lymphoedema; HF in implantable-device patients) and a blue-chip US customer list may be worth more to a larger medtech or survivorship player than the current equity value.
Bear case
-
Funding gap. A$15.3M cash at FY26 against ~A$18M trailing burn, a going-concern doubt, debt covenants, and option exercise prices 2–3× the share price imply further deeply dilutive capital raising.
-
Demand has disappointed. ARR has been flat for four quarters, churn has risen to 6.8%, and despite near-universal coverage US unit sales remain ~20–40 per quarter.
-
Competition and scale. Tactile Medical (US$329.5M revenue) now owns an assessment technology (LymphaTech) and a large lymphoedema sales channel; cheaper BIA/DXA options compete in body composition.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Late Oct 2026 | Q1 FY27 Appendix 4C — first full quarter of cost-out; ARR and US units under new CEO |
| Nov 2026 (expected) | 2026 AGM — remuneration vote, any capital-management resolutions |
| FY27 | FDA decision on sarcopenia 510(k) |
| FY27 | Heart Health: additional IDN wins; HF-Dex reimbursement mapping outcomes |
| FY27 | Weight-management conversion from 3,000+ leads |
| Ongoing | Churn rate trajectory and renewal pricing |
| Ongoing | SWK covenant headroom; option exercise behaviour (A$0.010/A$0.015 strikes) |
| Ongoing | Any strategic partnership/M&A announcements |
| Feb 2027 | H1 FY27 results — evidence on breakeven path |
Concluding analyst verdict
ImpediMed is a classic case of a clinically validated, commercially under-scaled medtech whose equity has been crushed by the cost of waiting for adoption. Every structural obstacle the company identified three years ago has been cleared: BIS is in NCCN and NAPBC guidance, a CPT code exists, US coverage has gone from zero to 95% of covered lives, and SOZO sits in the most prestigious cancer centres and IDNs in the country. Gross margins of 86–88% demonstrate that the product, once placed, is a high-quality recurring revenue stream.
Yet the financial outcome remains poor. FY2026 revenue of A$14.6M grew 15%, but ARR stalled at A$14.4M throughout the year, churn rose to 6.8%, and operating cash burn of A$17.9M exceeded revenue. The May–June 2026 recapitalisation — 1.62bn shares at A$0.007–0.010, a A$5M cost-out and partial SWK prepayment — bought time rather than solving the funding problem, and the auditor's going-concern doubt is the clearest signal of how thin the margin for error is. The FY28 breakeven target relies on option exercise at prices well above the current share price, which looks unlikely absent a sharp operational turnaround.
The investment debate therefore hinges almost entirely on whether Erik Anderson's US hospital-sales background can convert a ~700-unit pipeline into placements quickly enough to stabilise ARR growth at 20%+ before cash runs short, and whether the HF and GLP-1 adjacencies can contribute without additional fixed cost. We view IPD as a high-risk, binary, option-like security: the strategic asset value (unique clearances, guideline status, US footprint) provides a plausible floor via partnership or acquisition, but the base case for existing shareholders remains further dilution. Monitor Q1–Q2 FY27 ARR, churn and cash burn closely; absent visible acceleration, the equity is best treated as speculative only.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / background | Source |
|---|---|---|---|---|
Erik Anderson | Managing Director & CEO | Board from 25 Feb 2026; CEO from 7 Apr 2026 | Former Division President, Breast & Skeletal Health at Hologic; >25 years in US hospital sales, health-system account management and commercialisation | ASX 7 Apr 2026; Appendix 4D H1 FY26; MPO |
McGregor Grant | CFO & COO, Executive Director | Board since Sep 2023 (initially Chair; Executive Chair & interim CFO from Nov 2023); CFO from Feb 2024 | Board administration, governance and investor-relations experience | Strawman/Morningstar bios; InvestSMART |
Leanne Ralph | Company Secretary (Bellev) | Current | Outsourced company secretarial | Appendix 4E cover letter |
Dr Parmjot Bains | Former MD & CEO | Jan 2024 – 7 Apr 2026; adviser to 30 Jun 2026 | Healthcare executive with strategy, sales/marketing and commercial experience across the US, Asia, Middle East and Australia | ASX 7 Apr 2026; company bio |
Board of Directors
| Director | Role | Appointed | Background | Independence |
|---|---|---|---|---|
Christine Emmanuel-Donnelly (BSc) | Non-Executive Chair | 28 Sep 2023 | IP specialist; former commercialisation/IP leader at CSIRO and RMIT; ex-patent attorney (AU/UK firms, Unilever UK); NED of PolyNovo, Medical Developments International, Pikcha Holdings (Seminal) | Independent |
Erik Anderson | Managing Director & CEO | 25 Feb 2026 (NED), CEO 7 Apr 2026 | See above | Executive |
McGregor Grant | Executive Director, CFO & COO | Sep 2023 | See above | Executive |
Andrew Grant (BEE, MBA) | Non-Executive Director | 28 Sep 2023 | Medical-device and hospital-sector executive across Australia, USA, Europe, Asia | — |
Janelle Delaney (MBA) | Non-Executive Director | 28 Sep 2023 | Not detailed in sources reviewed | Independent |
Fiona Bones | Non-Executive Director | 7 Jun 2024 | Not detailed in sources reviewed | — |
Board & Management Changes
| Date | Change |
|---|---|
28 Sep 2023 | Four directors replaced by shareholder vote |
Nov 2023 | McGregor Grant Executive Chair & interim CFO; Dr Michael Seiden resigns (20 Nov 2023) |
Jan 2024 | Dr Parmjot Bains appointed MD & CEO |
7 Jun 2024 | Fiona Bones joins board |
25 Feb 2026 | Erik Anderson joins board |
7 Apr 2026 | Anderson becomes MD & CEO; Bains steps down (adviser to 30 Jun 2026) |
2 Jun 2026 | Two new commercial leadership roles created (sales, customer retention) |
Major Shareholders
| Holder | Stake | Date / source |
|---|---|---|
Acorn Capital Limited | 5.64% (131.9M shares) at time of notice; diluted post-raise (current % not disclosed) | Became substantial 7 May 2026 (FilingReader) |
Australian Ethical Investment | 4.73% (173.2M shares) — ceased to be substantial 1 Jul 2026 | Notice 3 Jul 2026 |
Other top-10 holders | Not publicly disclosed in sources reviewed (see 2026 Annual Report shareholder information) | — |
Free float | ~92% (MarketScreener) | Sep 2026 |
Director holdings | Small relative to issued capital; directors subscribed A$0.6M in the May 2026 placement (Tranche 2) plus fee-for-shares issues; Chair bought 1.5M shares on 5 Feb 2026 | ASX notices |
Competitive Landscape
Competitors by Segment
| End-market | Competitor | Offering | Relative positioning vs ImpediMed |
|---|---|---|---|
Lymphoedema assessment | Tape measurement / limb volumetry (standard practice) | Low-cost manual circumference | Incumbent standard of care; ImpediMed's core displacement target |
Lymphoedema assessment | Perometry (e.g., Pero-System) | Optoelectronic limb volume | Objective volume measure; lacks BIS's extracellular-fluid specificity |
Lymphoedema assessment | Tactile Medical — LymphaTech (acquired 2025/26) | 3D imaging limb measurement | New, well-funded competitor in assessment, integrated with a large lymphoedema-treatment sales force |
Lymphoedema treatment (adjacent) | Tactile Medical (Flexitouch, Nimbus) | Pneumatic compression devices | US$329.5M 2025 revenue; potential partner or rival in the survivorship pathway |
Lymphoedema assessment | Tissue dielectric constant devices (e.g., Delfin MoistureMeter) | Local tissue water | Niche alternative |
Body composition | InBody (Korea) | Multi-frequency BIA analysers | Global leader in BIA body composition for clinics/fitness; far larger scale; lacks ImpediMed's specific FDA lymphoedema/HF claims |
Body composition | seca (Germany) | Medical BIA (mBCA) | Strong hospital presence in Europe/US |
Body composition | DXA (Hologic, GE HealthCare) | Dual-energy X-ray absorptiometry | Gold-standard reference; higher cost, radiation, lower throughput |
Body composition / wellness | Evolt, Styku, Tanita, Bodystat, RJL Systems | Consumer/clinic BIA and 3D scanning | Price competition in GLP-1/wellness channel |
Dialysis/fluid | Fresenius Body Composition Monitor | BIS in renal care | Adjacent BIS application |
Heart failure monitoring | Abbott CardioMEMS | Implantable pulmonary-artery pressure sensor | Evidence-rich, invasive, premium |
Heart failure monitoring | Sensible Medical (ReDS) | Non-invasive lung fluid measurement | Direct non-invasive fluid competitor |
Heart failure monitoring | Bodyport (Cardiac Scale) | FDA-cleared impedance scale (same DSB product code) | Home-based remote monitoring competitor |
Heart failure monitoring | Device-based (e.g., Medtronic OptiVol in implantables), ZOLL HFMS | Embedded/wearable fluid metrics | Integrated with cardiology workflows |
Peer Comparison FY2026
| Metric | ImpediMed (FY2026, A$) | Tactile Medical (FY2025, US$) |
|---|---|---|
Revenue | 14.6M | 329.5M |
Revenue growth | 15% | 12% |
Gross margin | 87% | 75.9% |
Operating margin | ≈ −160% (derived, loss-making) | 8.9% (US$29.3M operating income) |
Net income | −24.9M | 19.1M |
R&D intensity | — | 2.6% (US$8.5M) |
“—” = not publicly disclosed.
Recent Developments
--



